Sunho Biologics, Inc. (SUNHO BIO-B) announced that the sole resolution at its Extraordinary General Meeting (EGM) on 27 August 2026—proposing the immediate appointment of Dr. Xia Long as a non-executive director—failed to secure shareholder approval.

Of the 156.67 million ordinary shares entitled to vote, 94.00 million votes (100.00%) were cast against the resolution, while no votes were cast in favour. Consequently, the proposal did not achieve the required simple majority and was rejected.

The company confirmed it held no treasury shares and had no repurchased shares pending cancellation as at the meeting date, ensuring that all issued shares were eligible to vote. No shareholders were obliged to abstain, and none expressed an intention to do so prior to the meeting.

Computershare Hong Kong Investor Services Limited acted as the independent scrutineer for the poll. Director attendance included Executive Director Ms. Jiang Xiaoling in person, with Chairman and Executive Director Mr. Zhang Feng and Independent Non-executive Directors Mr. Chan Heung Wing Anthony, Ms. Feng Lan, and Mr. Shi Luwen participating via electronic means.

Following the vote, the board composition remains unchanged, with Mr. Zhang Feng and Ms. Jiang Xiaoling as executive directors, and Mr. Chan Heung Wing Anthony, Ms. Feng Lan, and Mr. Shi Luwen serving as independent non-executive directors.